The persistent growth of renal disease is of concern in many populations. 1, 2 Cardiovascular complications lead in all causes of mortality among patients with chronic kidney disease (CKD), accounting for approximately 50% of deaths, 3 and current treatment strategies offer only modest improvements in extending life. 4 -6 Uremic cardiomyopathy is a classic problem in this at-risk population.
The complex pathogenesis of uremic cardiomyopathy is incompletely understood, with many classical and renal-specific factors contributing to its expression (Table 1) . 7, 8 In contrast to the general population, the relative importance of atherosclerotic coronary disease is diminished in CKD, 9 -13 and that of left ventricular hypertrophy (LVH), heart failure, and sudden cardiac death are increased, 14 -16 although many of these complications are well represented in this renal population. Experimental studies identify several intracellular signaling pathways vital to the pathogenesis of LVH, 17-19 a key feature of uremic cardiomyopathy. Of these, the phosphoinositide-3 kinase (PI3K)-Akt pathway is of particular interest, for its role not only in regulating the development of LVH but also in postnatal coronary angiogenesis, cardiac fibrosis, cellular apoptosis, and metabolic dysfunction. Furthermore, insulin resistance produces maladaptive alterations in the Akt pathway, enhancing its contribution to the development of uremic cardiomyopathy.
INSULIN RESISTANCE IN UREMIA AND THE AKT PATHWAY
Insulin resistance is an independent risk factor for cardiac disease in CKD. 20 -24 Early studies demonstrated that insulin resistance in uremia is the result of impaired glucose metabolism 25,26 unrelated to insulin receptor or GLUT4 transporter function. [27] [28] [29] [30] [31] The metabolic acidosis seen in CKD is partially responsible for uremic insulin resistance, because the insulin sensitivity of glucose metabolism is improved by correcting pH. 32 Dialysis therapy also partially corrects insulin resistance, 33 although resistance is still observed in 33% of patients who receive renal replacement therapy. 34, 35 Serum is capable of inducing insulin resistance, 36 suggesting a role for dialyzable toxins, potentially carbamoylated amino acids, which produce a postreceptor defect in glucose uptake in rats similar to that observed in patients with insulin resistance. 37 Although insulin resistance associates with impaired signal transduction along the pathway regulating insulin-mediated glucose uptake, clinical and experimental studies show intact insulin signaling along paths regulating some of insulin's pleiotropic actions (Figure 1) . 38 -41 The reactive hyperinsulinemia of insulin resistance, necessary to maintain serum glucose, may lead to upregulation of these effects. These disturbances in the effects of insulin are fundamental to the negative consequences of insulin resistance. Akt acts as a focal point for the dispersion of postreceptor signal among many of pleiotropic effector pathways of insulin, and although perturbations in Akt activity have been identified in many models of hypertrophic cardiac disease, its characterization in the uremic heart remains incomplete.
AKT SIGNALING PATHWAY
Akt, known previously as protein kinase B, is a serine/threonine protein kinase with homology to protein kinase A and protein kinase C. Three isoforms of Akt exist in mammals (Akt 1 through 3), although in the heart, Akt1 and Akt2 predominate. 42 In resting cells, Akt resides in the cytosol, and stimulation of either PI3K␣, through insulin or IGF-1, or PI3K␥, through Gprotein-coupled receptors, leads to generation of phosphatidylinositol-3,4,5-trisphosphate and recruitment of Akt to the plasma membrane (Figure 2) . 43 There, Akt is phosphorylated at two regulatory sites by phosphoinositidedependent kinases 1 and 2, respectively.
Phosphorylation of both regulatory sites is required for full activation of Akt, 44 which has a number of intracellular targets (Figure 2 ). The consequences of Akt activation vary greatly depending on the route of activation and its duration and the specific isoform affected. For example, in normal health, insulin-PI3K␣-Akt signaling induces physiologic hypertrophy, yet insulin-stimulated Akt activity also augments pathologic hypertrophy in the context of pressure overload 45 ; Akt activation through G-protein-coupled receptors and PI3K␥ results in pathologic hypertrophy. 46 -48 Furthermore, whereas Akt1 is the dominant isoform implicated in regulation of postnatal cardiac growth, 49 Akt2 plays the dominant role in coronary angiogenesis, glucose metabolism, and cell survival. 50 It is this variation that makes Akt such a vital signaling component.
AKT SIGNALING IN UREMIA
The integrity of Akt signaling in the uremic state is not fully elucidated; there are no clinical data and only incomplete experimental information. In one model of CKD, total Akt was suppressed after 3 months of uremia, 51 but phosphorylated Akt was not assessed. Another study demonstrated increased Akt phosphorylation 52 but did not determine total Akt expression. Neither study directly assessed Akt activity or determined the relative expression or activity of Akt1 and Akt2; however, it is apparent that uremia causes significant perturbations in the Akt system. In patients with diabetes and models of insulin resistance, inhibition of insulin-stimulated Akt2 activity is seen, but Akt1 activity is preserved. 39, 40 As described in the next section, this imbalance of Akt1 and Akt2 activity predicts a cardiac phenotype very similar to that seen in the uremic heart.
UREMIC CARDIOMYOPATHY
The cardinal features of uremic cardiac disease are LVH, reduced capillary density, fibrosis, and ventricular remodeling. Of these, LVH is predominant, increasing in prevalence from 26% of patients with stage 3 CKD to 75% of hemodialysis patients. 53 Hypertrophy is a powerful independent predictor of survival in CKD 54, 55 and regression of LVH is associated with reduced cardiovascular risk and improved survival. 56 
Ventricular Hypertrophy
Cardiac hypertrophy is an adaptive response to a variety of physiologic and pathologic stresses; however, hypertrophied hearts are more susceptible to in- 57 and epidemiologic studies show that LVH triggers a cascade of detrimental changes ultimately resulting in heart failure. 58 In the postnatal period, normal cardiac growth and physiologic hypertrophy are dependent on the insulin/IGF1-PI3K␣-Akt axis. 49,59 -68 Although pathologic hypertrophic stimuli do not activate this pathway directly, 63 long-term treatment with insulin produces pathologic hypertrophy, associated with increased Akt phosphorylation, 69 as does activation of Akt through GPCR-PI3K␥. 46 -48 Furthermore, high carbohydrate feeding during pressure overload accentuates pathologic hypertrophy, the degree of which directly correlates with the degree of hyperinsulinemia and increased phosphorylation of Akt. 45 Akt experiments on null mice demonstrated that Akt1, rather than Akt2, has a dominant effect on cardiac hypertrophy. 49 Overexpression of Akt1 also produces variable results, generating physiologic hypertrophy in some experiments 70 but pathologic hypertrophy in others. 68, 71, 72 This disparity may be explained by differences in extent, duration, and subcellular localization of Akt activity. The importance of chronicity is highlighted by experiments showing a clear progression from physiologic to pathologic hypertrophy when Akt1 overexpression was induced in adult mice for 2 to 6 weeks. 73 The transition to pathologic hypertrophy occurs in association with a decrease in capillary density, a feature typical of uremic cardiomyopathy. In contrast, nuclear-targeted overexpression of Akt1 does not lead to pathologic hypertrophy; instead, hearts display increased numbers of cardiomyocytes, enhanced contractility, and protection from ischemia-reperfusion injury (IRI). 74, 75 Thus, the insulin-Akt1 pathway is involved in both physiologic and pathologic cardiac hypertrophy. Both the route and context of activation (presence of concurrent stimuli for pathologic hypertrophy) are important in determining which will dominate, as are the duration and subcellular localization of Akt activity. In the human heart, Akt activity increases as hypertrophy deteriorates into heart failure, 76 although it is not clear whether this is a causal relationship. Experimental studies showed perturbations in both total and phosphorylated Akt in the uremic rat 51, 52 but did not determine the differential expression or activation of Akt1 versus Akt2; however, uremia exposes the heart to longterm increase of serum insulin concentrations in the context of increased afterload, a situation that worsens pathologic cardiac hypertrophy in association with increased total Akt phosphorylation. 45 
Angiogenesis
Physiologic growth of cardiomyocytes is accompanied by increased angiogenesis maintaining capillary density. In experimental and clinical studies of CKD, capillary growth failed to keep pace with myocyte hypertrophy, 77, 78 resulting in decreased density. This effect is not seen in experimental essential hypertension, suggesting it is specific to uremic cardiomyopathy.
Coronary angiogenesis is under the dual control of vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), both of which are upregulated during short-term cardiac Akt1 overexpression associated with physiologic hypertrophy. 73 In contrast, after chronic overexpression of Akt1 and consequent pathologic hypertrophy, VEGF and Ang-2 are downregulated in association with reduced capillary density. 73 Furthermore, short-term overexpression of Akt1 produces pathologic hypertrophy when VEGF is inhibited simultaneously, 73 and inhibition of VEGF during pressure overload accelerates the transition to heart failure. 79 Thus, during chronic experimental Akt1 activation, the stimulus for myocyte growth is maintained, but the stimulus for capillary growth declines, resulting in a drop in myocardial capillary density that contributes to the transition to heart failure. A similar state likely occurs within the uremic heart. 73, 78 Fibrosis Cardiac fibrosis in uremia has been recognized since the 1940s and was found in ex- perimental and postmortem studies of CKD. 80 -84 It is of the reactive type, a consequence of endothelial-to-mesenchymal transition 85 followed by activation and proliferation of new interstitial fibroblasts. 82, 83, 86 Compared with control hearts with a similar degree of hypertension and LVH, the uremic cardiac interstitium demonstrates increased expression of proinflammatory mediators, such as PDGF, with correspondingly increased fibrosis, suggesting renal disease enhances myocardial fibrosis. 80, 87 This interstitial fibrosis contributes to ventricular stiffness and diastolic dysfunction and cardiac dysrhythmias and may further compromise molecular exchange between cardiomyocytes and capillary bed.
Studies investigating the mechanisms underlying this fibrosis are scarce; however, experimental work implicates signaling through mammalian target of rapamycin (mTOR), a downstream target of Akt. 88 Although there was no evidence of increased phosphorylation of Akt in these studies, neither specific phosphorylation of Akt1 and Akt2 nor Akt activity was determined. Furthermore, the development of insulin resistance was not determined; therefore, although the delineation requires further clarification, fibrosis in CKD is mediated in part by activation of a profibrotic intracellular signaling mechanism involving mTOR. 89 Furthermore, in a nonuremic model, chronic hyperinsulinemia produced pathologic hypertrophy and fibrosis by activation of a complex network of intracellular pathways, including Akt, 69 whereas the use of peroxisome proliferator-activated receptor ␥ (PPAR-␥) agonists in models of salt-sensitive hypertension decreased cardiac hypertrophy and fibrosis in association with reduced Akt phosphorylation. 84 Furthermore, as mentioned already, chronic overexpression of Akt1 can produce cardiac fibrosis associated with LVH. 68, 71 Thus, although cardiac fibrosis is a feature of the uremic heart, knowledge of the underlying mechanisms is still sparse. There is direct evidence that downstream targets of Akt are involved, and evidence from nonuremic models confirms that perturbations in Akt signaling induce cardiac fibrosis.
The potential role of Akt in this process deserves further clarification.
Apoptosis
Outcomes after acute myocardial infarction in CKD remain poor, despite optimal conventional therapy, 90, 91 and experimental studies showed the increased susceptibility to IRI of uremic hearts. 92, 93 Previous work on IRI demonstrated that cell death occurs through necrosis and apoptosis and that inhibiting apoptosis during reperfusion significantly improves outcomes. 94 -96 Cardiomyocyte apoptosis also plays a causal role in the development of uremic 97 and nonuremic heart failure, whereas inhibiting apoptosis reduces cardiac dysfunction in heart failure. 98, 99 Maintaining cardiac function requires timely de novo production of ATP; however, the production of ATP is reduced within the uremic heart, as evidenced by a decreased phosphocreatine-ATP ratio. 92 In addition to uremic heart, this restriction has multiple causes, including decreased oxygen and substrate supply as a result of impaired capillarymyocyte exchange, metabolic remodeling, and alterations in creatine kinase. Compromised ATP synthesis also results in a loss of mitochondrial membrane potential and functional deterioration, resulting in a further decline in ATP production and contributing to the inability of the uremic heart to adapt to hemodynamic alterations, 92,100 a situation similar to that in the failing human heart. 101 Mitochondrial damage causes the release of cytochrome c triggering apoptosis and cell death, jeopardizing the survival of remaining cardiomyocytes. The importance of apoptotic cell death in the transition from compensated hypertrophy to heart failure is paramount. 99, 102 Akt stimulation is a potent antiapoptotic signal, and evidence demonstrates that upregulation of the PI3K␣-Akt pathway, by either administration of insulin/IGF-1 or genetic manipulation, reduces apoptosis and improves functional recovery in the face of IRI. 94, 96, [103] [104] [105] [106] [107] Furthermore, inhibition of the PI3K␣-Akt axis, either chemically or with dominant negative Akt, abrogates this protection. 94, 105 Targeted disruption of Akt isoforms demonstrates that Akt2 rather than Akt1 confers this antiapoptotic effect. 108 Acute activation of Akt2 is thus antiapoptotic and cardioprotective. Chronic Akt activation does not protect against cell loss from IRI and is in fact detrimental, 109 potentially as a result of Akt-mediated inhibition of PI3K, 109 again highlighting important differences between acute and chronic activation of the Akt pathway.
Remodeling

Metabolic
Under normal conditions, the adult heart displays a preference for oxidation of fatty acids, with 60 to 90% of ATP production resulting from this route and the remaining 10 to 40% from glucose and lactate and a small fraction from ketones 101 ; however, LVH is associated with downregulation of fatty acid oxidation and upregulation of glucose oxidation. 110, 111 One explanation for this is a switch to "oxygen efficient" fuels during times of metabolic stress. 112 Although this may be initially compensatory, it may contribute to cardiac injury by lipotoxicity 113 or loss of metabolic flexibility. 114 Certainly, in models of pressure overload hypertrophy, although cardiac basal glucose uptake is increased, insulin-stimulated uptake is impaired. 115, 116 The mechanism for this involves reduced GLUT4 translocation, rather than changes in GLUT4 or GLUT1 expression. 117 Within the uremic heart, expression of GLUT4 and GLUT1 transporters are also unchanged, although there is also some evidence for a defect in GLUT4 translocation in the early stages of experimental uremic cardiomyopathy 31 ; the situation in more advance uremic cardiomyopathy is unknown.
Akt2 regulates glucose influx into cardiomyocytes 108 by increasing translocation of GLUT4 118,119 while concurrently decreasing fatty acid oxidation through downregulation of transcription factors, such as PPAR-␣ and PPAR-␥ coactivator-1, 120 which are involved in regulation of fatty acid oxidation. 121 The net effect of acute Akt2 stimulation is increased glucose and decreased fatty acid oxidation, a beneficial effect during hypoxic conditions; however, once again, the consequences of acute and chronic Akt activation differ, with chronic stimulation increasing basal but significantly blunting insulin-stimulated glucose uptake as a result of decreased GLUT4 expression in insulin-sensitive intracellular vesicles, 122 a picture similar to that seen in hypertrophy with uremia. Reduced myocardial insulin sensitivity could lead to a decreased ability to increase ATP generation in times of need or alter substrate use to match supply, leaving it susceptible to energy depletion. Furthermore, chronic increases in glucose uptake enhance glucose metabolism through non-ATP-generating pathways, including the oxidative pentose phosphate and hexosamine biosynthetic pathways, both of which contribute to myocardial fibrosis and cell death. 113 
Calcium Cycling
Uremia is associated with depressed cardiac function at the level of the myocyte, [123] [124] [125] independent of gross alterations in cardiac structure, or ␤-adrenoreceptor desensitization. 123, 124 Although the underlying mechanism is not fully understood, two groups independently identified prolongation of the calcium transient, 123, 125 without a change in amplitude or rate of sarcoplasmic reticulum calcium release. 125 Recovery of the calcium transient is dependent on the sarcoplasmic calcium-ATPase (SERCA2a) and the sarcolemma sodium-calcium exchanger. In clinical and experimental studies, the transition from compensated hypertrophy to heart failure was associated with downregulation of SERCA2a expression, 126, 127 which was also seen in experimental uremia. 123 Consequently, the uremic cardiomyocyte is desensitized to calcium, requiring greater diastolic and systolic intracellular calcium concentrations to maintain contraction. 123 The delayed recovery of the calcium transient and increased diastolic intracellular calcium may translate into clinical diastolic dysfunction.
The insulin-Akt signaling pathway impinges on calcium cycling at several stages, with the net effect of chronic activation of Akt increasing the size of the calcium transient and thus myocyte contraction. Akt acts on L-type calcium channels, 128, 129 enhancing calcium influx, and sarcoplasmic reticulum calcium reuptake, increasing expression of SERCA2a 130 and phosphorylation of phospholamban. 75 Whether these components are direct substrates for Akt is not known; however, the reduced expression of SERCA2a seen in uremia might be predicted by a defect in Akt signaling related to uremic insulin resistance.
CONCLUSIONS
Insulin resistance is an established integral component of the uremic syndrome and suggests disruption in the balance of insulin's pleiotropic and metabolic actions. This imbalance may be more important than any individual defect and is reflected by differential alterations in the intracellular signaling pathways of insulin. In particular, the Akt pathway displays a discrete defect in Akt2 activity alone in other insulin-resistant states. As this Akt2 defect produces a compensatory hyperinsulinemia, Akt1 signaling may actually be upregulated, exacerbating the imbalance between Akt1 and Akt2 activity. This differential may explain many of the phenotypic features of the uremic heart. In particular, decreased activity of Akt2 predicts impaired insulin-stimulated glucose uptake, increased susceptibility to IRI, and a reduction in SERCA2a with its consequent effects on diastolic function. In turn, the preserved or chronically enhanced Akt1 effects produce cardiac hypertrophy associated with fibrosis and reduced capillary density. The overall effect generates a convincing mimic for uremic cardiomyopathy.
Although other factors and intracellular mechanisms are undoubtedly also of critical importance in the development of uremic cardiac disease, insulin resistance and alterations in Akt signaling warrant further investigation, particularly because therapies to manipulate this system are already in clinical practice and could be rapidly applied to the treatment of uremic cardiomyopathy. Already there is experimental evidence for thioglitazones increasing Akt activity and ameliorating IRI in ischemia/ reperfusion models 131, 132 and hypertrophy in pressure overload, 84 whereas rapamycin, targeting mTOR downstream of Akt, reduces cardiac hypertrophy and fibrosis in uremic mice. 88 With proper clinical study, targeting future therapies at these underlying cellular mechanisms of uremic cardiomyopathy may finally start to reduce the burden of uremic cardiomyopathy in the CKD population. 
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